Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2013, Article ID 268438, 7 pages
Clinical Study

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab

1Department of Optometry, School of Physics, Dublin Institute of Technology, Dublin, Ireland
2Institute of Eye Surgery and Institute of Vision Research, Whitfield Clinic, Waterford, Ireland
3Macular Pigment Research Group, Waterford Institute of Technology, Waterford, Ireland
4African Vision Research Institute, Faculty of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
5NH & MRC Centre for Clinical Eye Research, Department of Optometry and Vision Science, Flinders Medical Centre & Flinders University of South Australia, Bedford Park, Australia

Received 24 October 2012; Accepted 23 January 2013

Academic Editor: Chi-Chao Chan

Copyright © 2013 Sarah Sabour-Pickett et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (nv-AMD). Methods. Forty-seven eyes of 47 patients with nv-AMD, and corrected distance visual acuity (CDVA) logMAR 0.7 or better, undergoing intravitreal injections of ranibizumab, were enrolled into this prospective study. Visual function was assessed using a range of psychophysical tests, while mean foveal thickness (MFT) was determined by optical coherence tomography (OCT). Results. Group mean (±sd) MFT reduced significantly from baseline (233 (±59)) to exit (205 (±40)) ( ). CDVA exhibited no change between baseline and exit visits ( and , resp.). Measures of visual function that did exhibit statistically significant improvements ( for all) included reading acuity, reading speed, mesopic and photopic contrast sensitivity (CS), mesopic and photopic glare disability (GD), and retinotopic ocular sensitivity (ROS) at all eccentricities. Conclusion. Eyes with nv-AMD undergoing intravitreal ranibizumab injections exhibit improvements in many parameters of visual function. Outcome measures other than CDVA, such as CS, GD, and ROS, should not only be considered in the design of studies investigating nv-AMD, but also in treatment and retreatment strategies for patients with the condition.